# STAT+: Popular insulin product enters shortage as other pens leave market
Canonical URL: https://biopharmsignal.com/news/MARKET/stat-popular-insulin-product-enters-shortage-as-other-pens-leave-market-c3a6a199
Ticker: MARKET
Company: MARKET
Source: STAT News
Published: 2026-07-23 16:23 EST
Original Source URL: https://www.statnews.com/2026/07/23/sanofi-insulin-lantus-solostar-pen-reported-short-supply/?utm_campaign=rss
## Summary

The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.

## Article Body
People with diabetes who use a popular long-acting insulin pen made by Sanofi have had to become pharmacy scouts in recent weeks as they encounter supply issues.

The Lantus Solostar pen containing 3 mL of insulin glargine has been running low for several weeks due to increased demand “driven by broader market dynamics,” a Sanofi spokesperson told STAT. The issue is not technically considered a shortage by the Food and Drug Administration, but patients are nonetheless having trouble getting the medication, sometimes having to call multiple locations to find a pen.

“Our priority is ensuring patients have access to their medications,” the spokesperson said, noting the company is “accelerating production and expediting all incoming replenishment stock.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
## Recent Company News
- 2026-07-23 16:33 EST — [STAT+: European regulators take steps to bolster clinical trial transparency](https://biopharmsignal.com/news/MARKET/stat-european-regulators-take-steps-to-bolster-clinical-trial-transparency-73aade26) — Source: STAT News
- 2026-07-23 16:23 EST — [STAT+: Popular insulin product enters shortage as other pens leave market](https://biopharmsignal.com/news/MARKET/stat-popular-insulin-product-enters-shortage-as-other-pens-leave-market-c3a6a199) — Source: STAT News
- 2026-07-23 16:18 EST — [Senate health panel delays vote on CDC nominee](https://biopharmsignal.com/news/MARKET/senate-health-panel-delays-vote-on-cdc-nominee-6cfcdaaa) — Source: STAT News
- 2026-07-23 15:26 EST — [STAT+: What’s in the last-minute flurry of health care bills?](https://biopharmsignal.com/news/MARKET/stat-what-s-in-the-last-minute-flurry-of-health-care-bills-39fec163) — Source: STAT News
- 2026-07-23 14:58 EST — [FDA panel confronting peptide controversy](https://biopharmsignal.com/news/MARKET/fda-panel-confronting-peptide-controversy-b9e91564) — Source: STAT News
## Related News
- 2026-07-23 16:33 EST — MARKET — [STAT+: European regulators take steps to bolster clinical trial transparency](https://biopharmsignal.com/news/MARKET/stat-european-regulators-take-steps-to-bolster-clinical-trial-transparency-73aade26)
- 2026-07-23 16:30 EST — BRLI — [OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026](https://biopharmsignal.com/news/BRLI/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026-4b38e04c)
- 2026-07-23 16:18 EST — MARKET — [Senate health panel delays vote on CDC nominee](https://biopharmsignal.com/news/MARKET/senate-health-panel-delays-vote-on-cdc-nominee-6cfcdaaa)
- 2026-07-23 15:26 EST — MARKET — [STAT+: What’s in the last-minute flurry of health care bills?](https://biopharmsignal.com/news/MARKET/stat-what-s-in-the-last-minute-flurry-of-health-care-bills-39fec163)
- 2026-07-23 14:58 EST — MARKET — [FDA panel confronting peptide controversy](https://biopharmsignal.com/news/MARKET/fda-panel-confronting-peptide-controversy-b9e91564)